Infiltrating bladder urothelial carcinoma sarcomatoid variant
diseaseOn this page
Also known as infiltrating bladder urothelial carcinoma, sarcomatoid variant with heterologous elementsinfiltrating bladder urothelial carcinoma, sarcomatoid variant without heterologous elementssarcomatoid carcinoma of the urinary bladder
Summary
Infiltrating bladder urothelial carcinoma sarcomatoid variant (MONDO:0004278) is a cancer and 3 clinical trials. Top therapeutic interventions include pemetrexed and vinblastine. A subtype of sarcomatoid transitional cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | infiltrating bladder urothelial carcinoma sarcomatoid variant |
| Mondo ID | MONDO:0004278 |
| EFO | EFO:1000303 |
| DOID | DOID:7553 |
| NCIT | C39824 |
| UMLS | C1512743 |
| MedGen | 268929 |
| GARD | 0023907 |
| Anatomy (UBERON) | UBERON:0001255 |
| Is cancer (heuristic) | yes |
Also known as: infiltrating bladder urothelial carcinoma sarcomatoid variant · infiltrating bladder urothelial carcinoma, sarcomatoid variant with heterologous elements · infiltrating bladder urothelial carcinoma, sarcomatoid variant without heterologous elements · sarcomatoid carcinoma of the urinary bladder
Disease family
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › sarcomatoid carcinoma › sarcomatoid transitional cell carcinoma › infiltrating bladder urothelial carcinoma sarcomatoid variant
Related subtypes (2): kidney pelvis sarcomatoid transitional cell carcinoma, bladder sarcomatoid transitional cell carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03744793 | PHASE2 | ACTIVE_NOT_RECRUITING | Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer |
| NCT03912818 | PHASE2 | TERMINATED | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer |
| NCT02812420 | EARLY_PHASE1 | ACTIVE_NOT_RECRUITING | Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| PEMETREXED | 4 | 1 |
| VINBLASTINE | 4 | 1 |
| CHEMBL4788494 | 0 | 1 |
Related Atlas pages
- Drugs: Pemetrexed, Vinblastine